0000950170-24-107660.txt : 20240918
0000950170-24-107660.hdr.sgml : 20240918
20240918115410
ACCESSION NUMBER: 0000950170-24-107660
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240916
FILED AS OF DATE: 20240918
DATE AS OF CHANGE: 20240918
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FMR LLC
CENTRAL INDEX KEY: 0000315066
ORGANIZATION NAME:
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-42271
FILM NUMBER: 241306547
BUSINESS ADDRESS:
STREET 1: 245 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6175706339
MAIL ADDRESS:
STREET 1: 245 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER NAME:
FORMER CONFORMED NAME: FMR CORP
DATE OF NAME CHANGE: 19920717
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bicara Therapeutics Inc.
CENTRAL INDEX KEY: 0002023658
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-785-8308
MAIL ADDRESS:
STREET 1: 245 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
ownership.xml
4
X0508
4
2024-09-16
true
0002023658
Bicara Therapeutics Inc.
BCAX
0000315066
FMR LLC
245 SUMMER STREET
BOSTON
MA
02210
false
false
false
true
See Remark 1
false
Common Stock
2024-09-16
4
C
false
10818
A
10818
I
F-Prime Capital Partners Life Sciences Fund VII LP
Common Stock
2024-09-16
4
C
false
712430
A
723248
I
F-Prime Capital Partners Life Sciences Fund VII LP
Common Stock
2024-09-16
4
C
false
392085
A
1115333
I
F-Prime Capital Partners Life Sciences Fund VII LP
Series Seed Preferred Stock
2024-09-16
4
C
false
10818
D
Common Stock
10818
0
I
F-Prime Capital Partners Life Sciences Fund VII LP
Series B Preferred Stock
2024-09-16
4
C
false
712430
D
Common Stock
712430
0
I
F-Prime Capital Partners Life Sciences Fund VII LP
Series C Preferred Stock
2024-09-16
4
C
false
392085
D
Common Stock
392085
0
I
F-Prime Capital Partners Life Sciences Fund VII LP
On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110.
Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein.
Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VII LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.
Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
2024-09-18